Evidence map›Paper›PMID 32220217›Full record

ArticleHuman gene therapy2020

Adeno-Associated Virus D-Sequence-Mediated Suppression of Expression of a Human Major Histocompatibility Class II Gene: Implications in the Development of Adeno-Associated Virus Vectors for Modulating Humoral Immune Response.

Hyung-Joo Kwon, Keyun Qing, Selvarangan Ponnazhagan, Xu-Shan Wang, David M Markusic, Siddhant Gupte, Shannon E Boye, Arun Srivastava

Open access · greenAbstract read
In one paragraph

Article in Human gene therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. AAV vector development, back to the future.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Reply to "D" matters in recombinant AAV packaging.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Hyung-Joo KwonDepartment of Microbiology, Hallym University College of Medicine, Chuncheon, South Korea.
Keyun QingDivision of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA.
Selvarangan PonnazhaganDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Xu-Shan WangEli Lilly & Company, Indianapolis, Indiana, USA.
David M MarkusicDepartment of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Siddhant GupteDepartment of Ophthalmology, University of Florida College of Medicine, Gainesville, Florida, USA.
Shannon E BoyeDepartment of Ophthalmology, University of Florida College of Medicine, Gainesville, Florida, USA.
Arun SrivastavaDivision of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA.
University of Florida · USEli Lilly (United States) · USHallym University · KRIndiana University School of MedicineUniversity of Alabama at Birmingham · US

Funding

Engineering AAV for safe and efficient gene delivery to the human retinaR01EY024280 · NEI · UNIVERSITY OF FLORIDA · PI Shannon Elizabeth Boye · 2014 to 2026
$7.5M
Next Generation of Recombinant AAV Serotype Vectors for Gene TherapyR01HL097088 · NHLBI · UNIVERSITY OF FLORIDA · PI GAO, GUANGPING, HERZOG, ROLAND W. · 2010 to 2018
$5.4M
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectorsR01GM119186 · NIGMS · UNIVERSITY OF FLORIDA · PI ASLANIDI, GEORGE V, SRIVASTAVA, ARUN · 2017 to 2021
$1.5M
Safety and efficacy of optimized AAV3 vectors in murine and NHP liversR21EB015684 · NIBIB · UNIVERSITY OF FLORIDA · PI GAO, GUANGPING, SRIVASTAVA, ARUN · 2012 to 2013
$432k
AAV2 and hepatocellular carcinomaR21AI131328 · NIAID · UNIVERSITY OF FLORIDA · PI SRIVASTAVA, ARUN · 2017 to 2018
$408k
Development of Optimized AAV Serotype Vectors for Human Gene TherapyR41AI122735 · NIAID · MEDOSOME BIOTEC, LLC · PI SRIVASTAVA, ARUN · 2016 to 2016
$294k
NEI NIH HHS R01 EY024280NHLBI NIH HHS R01 HL097088NIAID NIH HHS R21 AI131328NIAID NIH HHS R41 AI122735NIBIB NIH HHS R21 EB015684NIGMS NIH HHS R01 GM119186
6 · The paper itself

Abstract

A 20-nt long sequence, termed the D-sequence, in the adeno-associated virus (AAV) inverted terminal repeat was observed to share a partial sequence homology with the X-box in the regulatory region of the human leukocyte antigen DRA (HLA-DRA) promoter of the human major histocompatibility complex class II (MHC-II) genes. The D-sequence was also shown to specifically interact with the regulatory factor binding to the X-box (RFX), binding of which to the X-box is a critical step in the MHC-II gene expression, suggesting that D-sequence might compete for RFX transcription factor binding, thereby suppressing expression from the MHC-II promoter. In DNA-mediated transfection experiments, using a reporter gene under the control of the HLA-DRA promoter, D-sequence oligonucleotides were found to inhibit expression of the reporter gene expression in HeLa and 293 cells by ∼93% and 96%, respectively. No inhibition was observed when nonspecific synthetic oligonucleotides were used. D-sequence oligonucleotides had no effect on expression from the cytomegalovirus immediate-early gene promoter. Interferon-γ-mediated activation of MHC-II gene expression was also inhibited by D-sequence oligonucleotides as well as after infection with either the wild-type AAV or transduction with recombinant AAV vectors. These studies suggest that the D-sequence-mediated downregulation of the MHC-II gene expression may be exploited toward the development of novel AAV vectors capable of dampening the host humoral response, which has important implication in the optimal use of these vectors in human gene therapy.

Indexed as

Immunity, HumoralTerminal Repeat SequencesAnimalsDependovirusDNA, ViralDown-RegulationGene Expression RegulationGenes, MHC Class IIGenetic TherapyGenetic VectorsHEK293 CellsHeLa CellsHistocompatibility Antigens Class IIHLA AntigensHumansMiceDNA, ViralHistocompatibility Antigens Class IIHLA AntigensRegulatory Factor X1AAVgene expressiongene therapyimmune responseMHC class II

Identifiers

PMID32220217
PMCPMC7232703
OpenAlexW3013849951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.